{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T01:06:04Z","timestamp":1711760764324},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"DOI":"10.7759\/cureus.57179","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T12:00:53Z","timestamp":1711713653000},"source":"Crossref","is-referenced-by-count":0,"title":["Sorafenib-Induced Erythema Multiforme Major and Severe Hepatic Failure in Metastatic Hepatocellular Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Houda","family":"Abrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounia","family":"Amzerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Zahra","family":"El Mrabet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.05.006","article-title":"Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond","volume":"68","author":"Raoul JL","year":"2018","unstructured":"Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: sorafenib and beyond. Cancer Treat Rev. 2018, 68:16-24. 10.1016\/j.ctrv.2018.05.006","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0012.7909","article-title":"Experience with sorafenib in 3 hospitals in Sao Paulo","volume":"18","author":"Camargo-Pinheiro-Alves R","year":"2019","unstructured":"Camargo-Pinheiro-Alves R, Viera-Alves DE, Malzyner A, Gampel O, Almeida-Costa TF, Guz B, Poletti P. Experience with sorafenib in 3 hospitals in Sao Paulo. Ann Hepatol. 2019, 18:172-6. 10.5604\/01.3001.0012.7909","journal-title":"Ann Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.03.008","article-title":"Anaphylaxis preceded by erythema multiforme with sorafenib: first case report","volume":"18","author":"Mantovani A","year":"2019","unstructured":"Mantovani A, \u00c1lvares-Da-Silva MR. Anaphylaxis preceded by erythema multiforme with sorafenib: first case report. Ann Hepatol. 2019, 18:777-9. 10.1016\/j.aohep.2019.03.008","journal-title":"Ann Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig M","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al.. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022, 76:681-93. 10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.10.981","article-title":"Sorafenib-induced erythema multiforme","volume":"56","author":"MacGregor JL","year":"2007","unstructured":"MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad Dermatol. 2007, 56:527-8. 10.1016\/j.jaad.2006.10.981","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2930","article-title":"Sorafenib-induced eruption mimicking erythema multiforme","volume":"152","author":"Pichard DC","year":"2016","unstructured":"Pichard DC, Cardones AR, Chu EY, Dahut WL, Kong HH. Sorafenib-induced eruption mimicking erythema multiforme. JAMA Dermatol. 2016, 152:227-8. 10.1001\/jamadermatol.2015.2930","journal-title":"JAMA Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015886","article-title":"Prednisone is not beneficial for the treatment of severe drug-induced liver injury: an observational study (STROBE compliant)","volume":"98","author":"Wan YM","year":"2019","unstructured":"Wan YM, Wu JF, Li YH, Wu HM, Wu XN, Xu Y. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: an observational study (STROBE compliant). Medicine (Baltimore). 2019, 98:e15886. 10.1097\/MD.0000000000015886","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26678","article-title":"Steroid use in acute liver failure","volume":"59","author":"Karkhanis J","year":"2014","unstructured":"Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, Brown RS Jr. Steroid use in acute liver failure. Hepatology. 2014, 59:612-21. 10.1002\/hep.26678","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.11.007","article-title":"Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors","volume":"90","author":"Ishak RS","year":"2014","unstructured":"Ishak RS, Aad SA, Kyei A, Farhat FS. Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors. Crit Rev Oncol Hematol. 2014, 90:152-64. 10.1016\/j.critrevonc.2013.11.007","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.014","article-title":"Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome?","volume":"42","author":"Strumberg D","year":"2006","unstructured":"Strumberg D, Awada A, Hirte H, et al.. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome?. Eur J Cancer. 2006, 42:548-56. 10.1016\/j.ejca.2005.11.014","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib","volume":"61","author":"Reig M","year":"2014","unstructured":"Reig M, Torres F, Rodriguez-Lope C, et al.. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol. 2014, 61:318-24. 10.1016\/j.jhep.2014.03.030","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2014.08.003","article-title":"Systemic treatment","volume":"28","author":"Reig M","year":"2014","unstructured":"Reig M, Gazzola A, Di Donato R, Bruix J. Systemic treatment. Best Pract Res Clin Gastroenterol. 2014, 28:921-35. 10.1016\/j.bpg.2014.08.003","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1363","article-title":"Sorafenib-induced acute-on-chronic liver failure in a patient with hepatocellular carcinoma after transarterial chemoembolization and radiofrequency ablation: a case report","volume":"7","author":"Wang QL","year":"2017","unstructured":"Wang QL, Li XJ, Yao ZC, Zhang P, Xu SL, Huang H, Hu KP. Sorafenib-induced acute-on-chronic liver failure in a patient with hepatocellular carcinoma after transarterial chemoembolization and radiofrequency ablation: a case report. Mol Clin Oncol. 2017, 7:693-5. 10.3892\/mco.2017.1363","journal-title":"Mol Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9249-4","article-title":"Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma","volume":"5","author":"Ogasawara S","year":"2011","unstructured":"Ogasawara S, Kanai F, Obi S, et al.. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int. 2011, 5:850-6. 10.1007\/s12072-010-9249-4","journal-title":"Hepatol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239123-sorafenib-induced-erythema-multiforme-major-and-severe-hepatic-failure-in-metastatic-hepatocellular-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T12:00:55Z","timestamp":1711713655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239123-sorafenib-induced-erythema-multiforme-major-and-severe-hepatic-failure-in-metastatic-hepatocellular-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.57179","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}